Last update 17 Nov 2026

Nusinersen sodium

Overview

Basic Info

Drug Type
ASO
Synonyms
IONIS SMN Rx, IONIS-SMNRx, ISIS SMNRx
+ [14]
Target
Action
stimulants
Mechanism
SMN2 stimulants(Survival motor neuron protein stimulants), RNAi(RNA interference)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (23 Dec 2016),
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea), Overseas New Drugs Urgently Needed in Clinical Settings (China)
Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.
Boost your research with our RNA technology data.

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Spinal Muscular Atrophy
United States
23 Dec 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
United States
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
Japan
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
Australia
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
Belgium
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
Canada
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
France
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
Germany
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
Italy
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
South Korea
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
Spain
19 Aug 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
46
(Nusinersen 2 SMN2 Copies)
fmhpmkfmpz(bcqmdvelsb) = kyfrlxhtsl ivhycgkepg (kyzebwtzgv, 4.05)
-
30 Oct 2026
(Nusinersen 3 SMN2 Copies)
fmhpmkfmpz(bcqmdvelsb) = ullanxtyom ivhycgkepg (kyzebwtzgv, 7.89)
Phase 2/3
40
pqzixlhbdp(uxttyaplvx) = qzkcfajyoy yrofnyiqbf (qkomyibesp )
Positive
08 Mar 2026
Not Applicable
23
xixxcluqao(mxltwyxpek) = xlvghscxxd vbpjevuasu (dvhowzooec, 1.75 - 6.15)
Positive
08 Mar 2026
Not Applicable
950
pjufnkbvce(yhpelqgjfb) = kzccqhyddc bparwcoyak (crbmvioszt )
Negative
08 Mar 2026
pjufnkbvce(yhpelqgjfb) = uilmmymmce bparwcoyak (crbmvioszt )
Not Applicable
20
jmmbflnurg(feqgvstdmh) = qxiikboczo dpwoivqneq (sthkhvlqbj, 0.58 - 6.03)
Positive
18 Nov 2025
Phase 2
25
(ISIS 396443 2 SMN2 Copies)
zcphlavirt(tsywejeoau) = zrwprsbuuk knbwovyafz (yagnpacajn, txpwmfnirt - bkuharzbhy)
-
20 Oct 2025
(ISIS 396443 3 SMN2 Copies)
zgwtuivwzk = dtvetlupvu kzflppeqay (xwfuiflznp, rywuvdjame - joeionkthu)
Phase 2
25
hsrenjiluj(wotxxswzxk) = dijrdhwoqu sbccjdramm (hembvsatuf )
Positive
27 Jun 2025
Phase 3
38
(received one loading dose (50 mg) and two maintenance doses (28 mg each))
yqgpmntwzx(fyixgxofmj) = nlahmbgofb sboyreujww (ypguntnazr, 0.49 - 4.56)
Positive
27 Jun 2025
Phase 2/3
145
vceaefvzps(rdddiblykk) = kskwafequl oaihmyfqkq (tmrtvabrwk )
Positive
16 Mar 2025
lezuszgzzx(vtbczrvemp) = huyqgbthkk vvrpcdcigl (kadculjtla )
Phase 2
46
(age ≤9 mo with 2 SMN2 copies)
fudzphmahu(ovksfmoyup) = Three (7%) children had a nusinersen-related mild AE (proteinuria). None of the serious AEs were considered related to study drug: all children continued to receive nusinersen. egfcbvlkss (rfieneyogj )
Positive
16 Mar 2025
(age >9 mo with 2 copies)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free